



Post-COVID Interstitial Lung Disease-The Tip of the Iceberg

Kewalramani, N., Heenan, K.-M., McKeegan, D., & Chaudhuri, N. (2023). Post-COVID Interstitial Lung Disease-The Tip of the Iceberg. *Immunology and allergy clinics of North America*, 43(2), 389-410.
<https://doi.org/10.1016/j.iac.2023.01.004>

[Link to publication record in Ulster University Research Portal](#)

Published in:

Immunology and allergy clinics of North America

Publication Status:

Published (in print/issue): 31/05/2023

DOI:

[10.1016/j.iac.2023.01.004](https://doi.org/10.1016/j.iac.2023.01.004)

Document Version

Author Accepted version

General rights

Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.

Title Page:

Title: Post COVID Interstitial Lung Disease - The tip of the iceberg

Authors: Namrata Kewalramani^{1,2}, Kerri-Marie Heenan³, Denise McKeegan³ and Nazia Chaudhuri⁴

Degrees:

Namrata Kewalramani-MD

Kerri-Marie Heenan – MB Bch BAO

Denise McKeegan - MB Bch BAO MSc

Nazia Chaudhuri –BSc,MD, PhD

Affiliations

1. Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
2. Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
3. Department of Respiratory Medicine, Antrim Area Hospital, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.
4. University of Ulster Magee Campus, Northland Road, Londonderry, Northern Ireland, UK.

Mailing addresses and Email addresses

Namrata Kewalramani-Namrata.kewalramani@gmail.com

Nazia Chaudhuri – nazia.chaudhuri@nhs.net

Kerri-Marie Heenan – kheenan01@doctors.org.uk

Denise McKeegan - dmckeegan02@qub.ac.uk

Corresponding Author

Namrata Kewalramani

Disclosure Statement:

Namrata Kewalramani reports grant and nonfinancial support from CSL Behring outside the submitted work.

Kerri-Marie Heenan has nothing to disclose.

Denise McKeegan has nothing to disclose.

Nazia Chaudhuri has nothing to disclose.

Word Count: 6817 including key points, text, figure legends and references – Manuscript target 4,500

Key Words (4-8 words to direct and optimize search results)

COVID-19

Post COVID-19 Condition (Long COVID)

Interstitial Lung Disease

Post COVID Fibrosis

Long Term Impact

Key Points (3-5 bulleted sentences indicating the main takeaways/defining elements of the article)

- Some patients have persistent symptoms, lung function impairment and radiological abnormalities post **SARS-CoV-2** infection.
- Post COVID fibrotic changes have shown resolution at 12 months, however in a cohort of patients the changes persist.
- The long-term impact of post COVID fibrosis remains unknown and ongoing studies are aimed at assessing the frequency and consequences of this new disease entity.
- Post COVID Interstitial Lung Disease (PC-ILD) may represent a significant burden on healthcare systems.

Synopsis (100 words or less)

The proportion of symptomatic patients with post COVID-19 condition (long COVID) represents a significant burden on the individual, as well as on healthcare systems. A greater understanding of the natural evolution of symptoms over a longer period of time and impacts of interventions will improve our understanding of the long-term impacts of COVID-19 disease. This review will discuss the emerging evidence for the development of Post

COVID Interstitial Lung Disease (PC-ILD) focusing on the pathophysiological mechanisms, incidence, diagnosis, and impact of this potentially new and emerging respiratory disease.

Introduction

On the 11th March 2020 the World Health Organisation (WHO) declared the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a global pandemic, commonly referred to as coronavirus 2019 (COVID-19) ¹. The first documented case was recognised in Wuhan, China in December 2019 ². As of November 2022, there have been over 550 million cases worldwide and over 6 million deaths associated with COVID-19 ³. The spectrum of presentations and symptoms with COVID-19 can vary widely from asymptomatic carriers to life threatening respiratory and multi-organ failure. The risk factors for the severity of COVID-19 are felt to correlate with increasing age, body mass index (BMI) and co-morbidities such as diabetes, obesity, cardiovascular disease, hypertension and chronic kidney disease ⁴⁻⁷.

The widespread collaborative efforts of governments, public health, pharmaceutical industry and researchers has led to a wealth of expertise in tackling the pandemic over a relatively short period of time. We have effective therapies that can reduce the symptom burden and risk of hospitalisation and in-hospital mortality with COVID-19. Antivirals, monoclonal antibodies, and immunomodulatory drugs have emerged through robust trials as treatments for SARS-CoV-2 infection^{8,9}. Several therapies have been shown to reduce risk of hospitalisation in patients with mild to moderate disease. Treatment of symptomatic COVID-19 with Paxlovid, a SARS-CoV-2 protease inhibitor consisting of nirmatrelvir and ritonavir, has led to a reduction of severe COVID-19 by 89%, without evident safety concerns¹⁰. In non-hospitalised patients with mild to moderate COVID-19 disease Molnupiravir reduces the risk of hospitalisation or death by approximately 50% ¹¹⁻¹³. Coupled with the roll out of mass vaccination programs world-wide we have seen the mortality from COVID-19 declining despite continued high rates of infection^{14,15}.

Whilst we are grappling with the changing nature of the virus and attempting to rebuild our lives and economies, we are now faced with an emerging yet unquantifiable health epidemic –post COVID-19 condition (Long COVID). This review will discuss the emerging evidence for the development of Post COVID Interstitial Lung Disease (PC-ILD) focusing on the pathophysiological mechanisms, incidence, diagnosis, and impact of this potentially new and emerging respiratory disease.

Pathophysiology of Post COVID Interstitial Lung Disease

Data from previous coronavirus outbreaks of Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) suggest that between 25-35% of survivors will experience long-term respiratory complications with lung function and radiographic abnormalities consistent with the development of pulmonary fibrosis, therefore raising the suspicion that persistent respiratory symptoms post SARS-Cov-2 infection may have similar pathophysiological mechanisms to MERS and SARS infections^{7,16-20}.

A number of histopathological findings have been identified among COVID-19 cases. Gross examination of post-mortem specimens revealed that tissue damage was more severe in the lung peripheries, where fibrous tissue proliferation in the alveolar septa and alveolar destruction were remarkably abundant. In the central areas, the alveolar structure was roughly preserved with only focal fibrosis²¹. The most commonly reported histological pattern of lung injury is diffuse alveolar damage (DAD) with two identifiable stages; an acute stage, defined by scattered or diffuse hyaline membranes, associated with alveolar oedema, an alveolar eosinophil exudate and few vacuolated macrophages, and a more organised stage of parenchymal collapse, enlargement of alveolar septa, alveolar fibrin deposits, hyperplasia of type-2 pneumocytes, sparse multinucleated giant cells and minor fibroblast proliferation^{22,23}. A lung cryobiopsy study performed in patients with mean disease duration of 31.3 days observed marked fibrotic lung parenchymal remodelling, characterised by fibroblast proliferation, airspace obliteration, and micro-honeycombing²⁴.

According to a meta-analysis of COVID-19 inpatients, 14.8% developed acute respiratory distress syndrome (ARDS)²⁵. DAD has long been considered the hallmark histologic finding in acute ARDS²⁶. Pulmonary fibrosis (PF) subsequent to ARDS is well-recognised and given the relatively high incidence of ARDS among COVID-19 patients^{25,27}, PC-ILD as a potential long-term outcome of COVID-19 is concerning. Distinct from the idiopathic form of PF or other progressive ILD, fibrosis resulting from ARDS is largely stable. However, whereas some patients with fibrosis post-ARDS may fully recover, some may have lasting symptoms of decreased lung function²⁸. In post-mortem studies of those with COVID-19 features suggestive of a fibrotic phase, such as mural fibrosis and microcystic honeycombing, these findings were observed to be focal, rather than widespread. This may be due to the short duration of the disease at the time of death²².

The underlying pathology of ARDS is complex, and the inflammatory response and immune system play a critical role²⁹. In general, there is conflicting evidence regarding the possibility that viral infection may predispose one to the development of fibrosis. It is postulated that chronic viral infection may contribute to the fibrotic response through the promotion of a state of mild but chronic inflammation, which disrupts homeostasis and healing, thereby leading to increased susceptibility to a secondary insult. Coronavirus infection tends to have an acute duration; however, there is evidence from ARDS that even a duration of less than one week can lead to fibrosis³⁰. Inflammation promotes viral clearance, but excessive cytokine response can be damaging³¹.

Viruses can upregulate expression of critical host cell surface receptors, signalling pathways, and production of growth factors. The angiotensin converting enzyme 2 (ACE2) receptor, which is engaged by the S1 subunit of the SARS-CoV-2 spike protein, acts as a regulator of the renin-angiotensin system (RAS) which activates a broad range of signalling pathways including proinflammatory and profibrotic effects. Inflammation promotes viral clearance, but excessive cytokine response can be damaging³¹. Cytokines such as transforming growth factor [TGF]- β , interleukin [IL]-6, tumour necrosis factor [TNF]- α , and chemokines promote activation of immune populations that clear infection and promote immunity through T-cell and B-cell recruitment. They also activate macrophage populations that clear apoptotic cellular debris. In acute lung injury, activated macrophages also contribute to induction of neutrophil recruitment and activation³². Neutrophilic infiltrate, in turn, contributes to generation of reactive oxygen species (ROS) and both neutrophilic infiltrate and ROS may contribute to tissue injury^{33,34}. In response to injury alveolar epithelial cells recruit fibroblast and inflammatory cells to initiate wound healing by reshaping the extracellular environment to restore tissue integrity and promote the replacement of parenchymal cells³⁵. Usually, this pro-fibrotic process is turned off once the tissue heals. However, repeated damage and repair, such as that seen in SARS-CoV-2 infection, can lead to the imbalance of this process, resulting in excessive pathological deposition of extracellular matrix (ECM) protein, accompanied by upregulation of myofibroblast activity, resulting in a chronic inflammatory environment of macrophage and immune cell infiltration. This is supported by a study on lung samples from individuals who succumbed to COVID-19 and control individuals using single-nucleus RNA-sequencing. They noted a reduction in the epithelial cell compartment, of both alveolar type 1 and 2 cells, and an increase in monocytes/macrophages and fibroblasts in COVID-19 patients as compared to control lungs³⁶. Furthermore, in a multi-omics study of postmortem COVID-19 patients there was hyperinflammation, alveolar epithelial cell exhaustion, vascular changes and fibrosis, and

parenchymal lung senescence as a molecular state of COVID-19 pathology. A forkhead transcription factor, FOXO3A suppression was implicated as a potential mechanism underlying the fibroblast-to-myofibroblast transition associated with PC-ILD.³⁷ In this cellular environment, massive proinflammatory and profibrotic cytokines are released, thus activating fibrosis-related pathways including the TGF- β signal pathway, Wingless/Integrated (WNT) signal pathway and yes-associated protein/transcriptional cofactor with PDZ binding motif (YAP/TAZ) signal pathways^{38,39}.

FIGURE 1 COMES HERE - (Figure 1 was created with BioRender.com.)

Figure 1 illustrates how viruses can upregulate expression of critical host cell surface receptors, signalling pathways, and production of growth factors. The ACE2 receptor acts as a regulator of the renin-angiotensin system (RAS) which activates a broad range of signalling pathways including proinflammatory and profibrotic effects.

A significant proportion of patients with severe COVID-19 required invasive mechanical ventilation (IMV). IMV can induce stretch force injury and alveolar injury and may contribute to ARDS. Increased lung stretch can induce oxidative injury, increase cytokine production, increase epithelial-mesenchymal transition (EMT)^{40,41} and increase collagen deposition in the lungs which contributes to the development of PF. Careful ventilation of injured lungs, or lungs that may have increased stiffness, could potentially help to minimize ventilator-induced profibrotic signaling⁴⁰.

Persistent Symptoms Post COVID

Whilst the majority of patient's symptoms recover within 4-8 weeks of a SARS-CoV-2 infection, some find their symptoms will persist beyond 12 weeks, leading to the term "Long COVID"^{42,43}. The WHO has defined "Post COVID-19 (Long COVID)" as a condition occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis". Studies have shown up to 48.8% of individuals reporting not feeling fully recovered from COVID-19 with a median of nine persistent symptoms one year following SARS-Cov-2 infection (Table 1) with the most reported symptoms being breathlessness and fatigue⁴⁴⁻⁴⁷. Female gender, being middle age (40-59 years), having two or more self-reported co-morbidities and experiencing a

more severe form of COVID-19 at the time of diagnosis and resultant hospitalisation had a lower rate of self-reported recovery^{6,44,45}

Table 1

Commonly reported persistent symptoms post COVID-19

- Breathlessness
- Fatigue
- Impaired sleep quality
- Aching of muscles (pain)
- Physical slowing down
- Joint pain or swelling
- Limb weakness
- Pain
- Short-term memory loss
- Slowing down in thinking

Data from references⁴⁴⁻⁴⁷

Persistent symptoms of COVID-19 have been reported in early phases and late phases of follow up (Table 2). As time has elapsed since the emergence of the novel SARS-CoV-2 infection, we are beginning to appreciate the longer-term symptom burden. Two large prospective observational studies looking at long term outcomes after SARS-CoV-2 infection, the Lung Injury COVID-19 study and the Post Hospitalisation COVID-19 study (PHOSP- COVID) have followed up 305 Spanish and 1077 UK patients respectively^{46,48}. The Lung Injury COVID-19 study stratified patients according to severity of SARS-CoV-2 infection as moderate disease (features of pneumonia with oxygen saturations above 90% requiring supplemental oxygen, n=162) or severe disease (patients who required either non-invasive ventilation, high flow oxygen or intubation and IMV, n=143). At medium term follow up classed as less than 180 days from initial symptoms, 55.5% of patients with severe disease and 44.1% of patients with moderate disease had persistent dyspnea with a modified Medical Research Council (mMRC) dyspnea scale of above 2. Dyspnea was significantly more prevalent in the severe group than the moderate group ($p=0.042$). At this time point only 13.5% of patients had symptom resolution and other persistent symptoms included chest pain, fatigue, and cough with no differences in frequency between the moderate and severe groups⁴⁸. Beyond 10 months, one third of patients' symptoms had resolved; however, breathlessness (mMRC>2) remained in 18.4 and 20% of the moderate and severe groups

respectively. Intriguingly, patients with moderate disease severity had a higher symptom burden at this later time point than those with severe disease, including cough (11.9 vs 3%; $p=0.03$), chest pain (14 vs 4.4%; $p=0.025$) and fatigue (20 vs 7.7%; $p=0.017$). This suggests that ongoing symptoms do not correlate with the severity of the acute COVID-19 illness⁴⁹. In the PHOSP-COVID study only 239 of 830 (28.8%) individuals described themselves as fully recovered at a median of 5.9 months (Interquartile range 4.9-6.5) post hospital discharge. 632 of 855 (92.8%) individuals had at least one persistent symptom with a median of nine symptoms (Table 1)⁴⁵.

A persistence of respiratory symptoms at one year follow-up in a subset of patients after acute COVID-19 highlights the potential for ongoing respiratory sequelae and the need for continued monitoring of this group of patients. With over 550 million people affected world-wide³, up to 20% may have continued respiratory symptoms at a year equating to a staggering 110 million people. This proportion of symptomatic patients with post COVID-19 condition (long COVID) represents a significant burden on the individual, as well as on healthcare systems. A greater understanding of the natural evolution of symptoms over a longer period of time and impacts of interventions will improve our understanding of the long-term impacts of COVID-19 disease. Persistent respiratory symptoms have a complex aetiology and are not always attributable to underlying parenchymal disease. Whilst the natural assumption is that these symptomatic patients may have underlying structural changes such as pulmonary fibrosis, one needs to be mindful that deconditioning, overall wellbeing such as the presence of anxiety and depression and muscle weakness/fatigue may also be contributing to ongoing breathlessness. Objective evidence of pulmonary abnormalities with pulmonary physiology and advanced radiology is therefore paramount.

Table 2 Published reports on symptoms post SARS-CoV-2 infection													
	MANDEL et al. ⁴⁴	CARFI et al. ⁴⁷	WILLI et al. ⁵⁰	FROIDURE et al. ⁵¹	BOARI et al. ⁵²	ROBERY et al. ⁵³	FAVERIO et al. ⁵⁴	HAN et al. ⁵⁵	HAMA AMIN et al. ⁵⁶	ZANGRILLO et al. ⁵⁷	HUANG et al. ⁵⁸	FAVERIO et al. ⁵⁹	EVANS et al. ^{45,46}
Type of study	Cross sectional study	Prospective cohort	Systematic literature search of 31 studies	Single center cohort study	Prospective Cohort	Retrospective analysis	Multicenter prospective observational cohort	prospective longitudinal study	Meta analysis of 618 articles	prospective observational study	ambidirectional cohort study	Multicenter prospective observational cohort	Prospective, longitudinal cohort study
Country	United Kingdom (UK)	Italy	Switzerland	Belgium	Italy	UK	Northern Italy	China	Worldwide	Italy	Wuhan, China	Northern Italy	Multicenter, UK
Duration of follow up	Median 54 days (IQR 47-59)	Mean 60.3 days (SD 13.6)	9-90 days	Median 95 days	Average 4 months	8-18 weeks	6 months	6 months	Up to 7 months	12 months	6 and 12 months	11-13 months	2-14 months post discharge
Number of patients	384	142	48,258	134	94	221	312	114	2018	116	1276	287	2320 at 5 months 807 at 1 year
Persistent symptoms	71.9%	87.4%	66-87.4%	-	-	100% ⁴ 21% ⁵	-	-	-	-	68% ⁸ 49% ⁹	-	54.9% ¹⁰ 48.8% ⁹
Specific symptoms													
Fatigue	67.3% ¹ 73.3% ² 76.9% ³	53.1%	16.36%- 72%	25%	52%	-	-	-	38.7% ⁶ 80% ⁷	-	52% ⁸ 20% ⁹	-	-
Dyspnea	54.8 % ¹ 63.3% ² 57.7% ³	43.4%	14.55-74.3%	35%	36%	-	38%	6.1%	26.6% ⁶ 50% ⁷	7% (at rest) 46% (on exertion)	26% ⁸ 30% ⁹	40%	-
Cough	32.2% ¹ 36.7% ² 46.2% ³	-	61%	10%	-	-	-	10%	15.5% ⁶ 31.6% ⁷	-	-	-	-
Joint /muscle pain	-	27.3%	27.3%	-	-	-	-	-	15.4% ⁶ 58.3% ⁷	-	11% ⁸ 12% ⁹	-	-
Chest pain	-	21.7%	21.7%	-	-	-	-	-	8% ⁶ 30.5% ⁷	39%	5% ⁸ 7% ⁹	-	-
Poor Sleep Quality	61.1% ¹ 93.3% ² 76.9% ³	-	24%	-	31%	-	-	-	-	-	27% ⁸ 17% ⁹	-	-
Headache	-	-	18.18 -61%	-	-	-	-	-	-	-	2% ⁸ 5% ⁹	-	-
GI symptoms	-	-	31%	-	-	-	-	-	-	-	1% ⁸ 1% ⁹	-	-
Physiological distress	-	-	23.5-46.9%	-	21%	-	-	-	-	36%	23% ⁸ 26% ⁹	-	-
Comments		-	11 prospective cohort 11 retrospective cohort 4 cross sectional 5 case reports	-					13 studies used	-		-	

SD = Standard Deviation, IQR = Inter Quartile Range, CPAP= Continuous Positive Airway Pressure, IMV= Invasive Mechanical Ventilation, ICU= Intensive Care Unit.
¹=Oxygen alone, ²=CPAP, ³=IMV, ⁴=Required ICU, ⁵= Did not require ICU, ⁶=Non Fibrotic group, ⁷=Fibrotic group, ⁸=6 months, ⁹=12 months, ¹⁰=5 months.

Pulmonary Function Impairment Post COVID-19

Pulmonary function abnormalities are seen as early as two weeks post discharge of an acute **SARS-CoV-2** infection. In a retrospective observational study of 137 patients from China, 81% of patients demonstrated an inspiratory vital capacity (IVC) of less than 80% predicted and 24.1% of patients had a forced vital capacity (FVC) of less than 80% predicted. The degree of restrictive ventilatory impairment correlates with severity of acute **SARS-CoV-2** infection^{60,61} and impairment was greatest in those patients that required intensive care unit (ICU) admission, of which 50% required intubation and IMV⁴⁹. Lung function impairment had poor correlation with the presence of respiratory symptoms, however a correlation between biomarkers involved in host defence reflecting neutrophil activation (Lipocalin-2), fibrosis signalling (matrix metalloproteinase-7) and alveolar repair (hepatocyte growth factor) and reduction in FVC and diffusing capacity for carbon monoxide (DLCO) was found⁴⁹.

Several studies have shown persistent lung function abnormalities at 3 and 4 months follow up^{20,51,53,62-65} (Table 3). The principal study out of Wuhan, China showed that in 83 patients who did not require IMV, 55% of patients had a DLCO less than 80% predicted and 23% had an FVC of less than 80% predicted at 3 months post discharge²⁰. Similar findings in DLCO and FVC decline were seen in Canadian, Belgian, French and UK cohorts^{51,53,62,63}. Impairments in lung function do not correlate with persistent symptoms⁵¹, however were related to severity of COVID-19 as defined as need for IMV^{63,65}, ICU admission^{51,53,63}, percentage inspired oxygen^{53,65} and days on inspired oxygen⁶². Correlations were also seen with age and severity of initial lung involvement⁶³.

Longitudinal follow up has shown that lung function impairments improve over time^{20,54,59,66,67}. However, even after a year post COVID-19, a proportion of patients will continue to have lung function impairment, raising the suspicion of long-term pulmonary complications such as the development of pulmonary fibrosis. In a Chinese study of 83 patients, 33% of patients had a DLCO less than 80% predicted at 12 months compared to 55% at 3 months and 11% of patients had an FVC less than 80% predicted at 12 months compared to 23% at 3 months²⁰. Similar improvements albeit persistent impairments in lung function parameters were observed in a Dutch study of 92 patients where frequency of impaired FVC improved from 25% at 6 weeks to 11% at 6 months, and for DLCO this percentage improved from 63% to 46%⁶⁶. Larger multicentre prospective studies have corroborated these findings and have identified risk factors for persistent lung function impairment as having asthma as a

comorbidity^{54,59}, female gender⁶⁷ and age^{48,67} Persistent lung function abnormalities highlight underlying structural lung involvement as a mechanism of ongoing respiratory symptoms post COVID and necessitate further radiological assessment.

Table 3 Published reports on pulmonary function testing post SARS-CoV-2 infection									
Study	Type of study	Country	Population / data	Duration of the study	DLCO predicted %	Alterations in DLCO (<80% predicted)	FVC % predicted	Alterations in FVC (<80% predicted)	Comments
LV et al. ⁶¹	Retrospective analysis	Taizhou, China	137 patients	2 weeks following discharge	-	-	-	55.6%	The degree of restrictive ventilatory impairment correlated with severity of acute SARS-CoV-2 infection. Evidence of small airway dysfunction at much lower frequency.
FROIDURE et al. ⁵¹	Single center cohort study	Belgium	134 patients	Median 95 day interval	Median 74%	46%	Median 88%	-	Impairments in lung function do not correlate with persistent symptoms. Impairments in lung function correlated with ICU admission
ROBEY et al. ⁵³	Retrospective analysis	United Kingdom	221 patients	8-18 weeks	Mean 76.6%	53%	Mean 86.5%	-	Alterations more common in patients requiring ICU. DLCO alterations more frequent with abnormal CT findings
FRIJA-MASSON et al. ⁶³	Retrospective study	Paris, France	137 patients	3 months after symptom onset	Median 49%	-	Median 98%	-	Alterations in PFT correlated to age, degree of initial lung involvement and endotracheal intubation.
GULER et al. ⁶⁴	multicenter prospective cohort	Switzerland	113 patients	4 months	Mean 73.2	-	Mean 86.6%	-	Alterations more pronounced in patients who had severe/critical COVID-19 versus mild/moderate COVID-19
SAFONT et al. ⁶⁷	multicenter prospective cohort	Spain	313 patients	2 months (mean 63±12 days) and 6 (mean 181±10 days) months after discharge	Mean 77.25% (2 months) 81.50 (6months)	54.63% at 2 months 46.96% at 6 months	Mean 99.02 (2 months) Mean 100.59 (6months)	14.38% (2 months) 9.27% (6 months)	FVC % predicted improved over time. Increase risk of DLCO impairment at 6 months was age D-dimer peak value, female sex and peak RALE score
FAVERIO et al. ⁵⁴	multicenter, prospective, observational cohort study,	Northern Italy	312 patients	6 months from discharge	Median 76.0% vs 84.0% vs 77.4% (oxygen vs CPAP vs IMV)	58% vs 36% vs 54% (oxygen vs CPAP vs IMV)	Median 107.2% vs 106.4% vs 102% (oxygen vs CPAP vs IMV)	-	Patients with COVID-19 who required oxygen has less impairment on PFT compared to patients requiring CPAP and patients requiring IMV
FAVERIO et al. ⁵⁹	multicenter, prospective, observational cohort study,	Northern Italy	287 patients	11-13 months from discharge	Median 79.0 vs 88% vs 80% (oxygen vs CPAP vs IMV)	53% vs 29% vs 49% (oxygen vs CPAP vs IMV)	Median 108.0%, 110.0% vs 106.5% (oxygen vs CPAP vs IMV)	-	Improvement from 6 to 12 months. Patient who required less respiratory support had less alterations in PFT.
TARRASO et al. ⁶⁸	Multicentre prospective observational cohort study	Spain	284 patients	12 months	-	53.8% vs 46.8% vs 39.8% 60 days vs 180 days vs 365 days	-	14.32% vs 9.29% vs 6.69% 60 days vs 180 days vs 365 days	Age, female sex and BMI risk of DLCO impairment at 365 days

DLCO = Diffusing Capacity for Carbon Monoxide, FVC= Forced Vital Capacity, ICU = Intensive Care Unit, CT= Computed Tomography, RALE= Radiological Assessment of Lung Edema, CPAP = Continuous Positive Airway Pressure, IMV = Invasive Mechanical Ventilation

Radiological Features Post COVID-19

In a retrospective study out of the Lombardy region in Italy, the worst hit region in Europe, 90 consecutive hospitalised patients had computerised tomography (CT) performed on admission and 60 days post discharge. On admission 90% of patients had bilateral lung disease with an 80% peripheral and 63% mid and lower-zone predominance. 54.4% demonstrated diffuse ground glass opacities (GGO) and 46.6% had both GGO and consolidation. CT images were reported as fibrotic based on the presence of reticulation, architectural distortion, traction bronchiectasis and honeycombing. 23 (25.5%) patients were defined as having a non-specific interstitial pneumonia (NSIP) pattern by two thoracic radiologists with over 30 years' experience. Patients with features of fibrosis on their imaging were of older age and had evidence of systemic inflammation with statistically higher lactate dehydrogenase (LDH), c-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, evidence of bone marrow suppression with reduced haemoglobin, white cell counts and platelets, and corresponding reductions in lung function parameters (FVC and DLCO) compared to individuals without features of fibrosis on their imaging⁶⁹ These findings were similar to studies out of Wuhan, China where 46% of patients at a median of 56 days follow up had CT evidence of fibrotic changes manifesting as parenchymal bands (76%), irregular interface (32%), traction bronchiectasis (38%), lung distortion (25%) and honeycombing (9%). The fibrosis was predominantly peripheral in distribution (89%), corresponding with the areas of acute COVID-19 changes, and the overall burden of fibrosis was minimal or mild in the majority (84%) of patients⁷⁰ In 50% of this cohort initial features of lung distortion attributed to fibrosis improved, suggesting a reversible element to these changes. On multivariate analysis, fibrosis was associated with higher ESR, eosinophil counts and advancing age. There were more patients in the fibrosis cohort who required non-invasive ventilation and 77% of the overall cohort was defined as having severe SARS-CoV-2 infection⁷⁰. A further study of 216 discharged patients found that 85.1% had CT abnormalities at 3 months and these were more frequent in patients defined as severe/critical or required IMV or high flow oxygen. There was also a significant negative correlation to total lung capacity (TLC) and residual volume (RV) and a weaker correlation to DLCO on lung function testing ($P < 0.05$)⁷¹. These early studies raised several questions as to whether features defined as fibrotic during early imaging are reversible over time and thus highlighted the need for longer follow up studies, or whether the severity of COVID-19 or need for IMV is driving the development of fibrosis. One such study found that at 4 months follow up, 44.4% of patients had a multi-disciplinary diagnosis of Interstitial Lung Disease (ILD) on CT imaging. 56% had evidence of

architectural distortion and this correlated with reductions in DLCO. The majority of patients with ILD at 4 months were admitted to ICU (6.3% vs 93.8%; $p=0.001$) and required IMV, high flow oxygen or underwent prone ventilation, and also had more complications of venous thromboembolism (VTE) and ARDS during their acute illness⁶⁵. Highlighting a potential role of severity of infection and IMV as risk factors and contributors to the development of fibrosis. Furthermore, in a study of 220 patients with 20% incomplete CT resolution at 6 months, predictors of persistent CT abnormalities were older age, prolonged hospital stay, a lower PaO₂/FiO₂ at hospital admission, higher degree of support and higher oxygen requirements⁷². The presence of reticulations and consolidation on CT at hospital admission predicted the persistence of radiological abnormalities during follow up⁷².

A systematic review of 31 studies found abnormal CT findings in 39-83% of patients with five studies describing pulmonary fibrosis at 3 months⁵⁰. Longitudinal serial CT studies over 3 and 6 months showed that fibrosis like findings were more prominent with severe SARS-CoV-2 infection (24.3% (17/70) vs 52.0% (53/102)) and that even with severe disease these findings could improve over time with 24% and 52% improvement seen in severe and moderate disease respectively. Radiological abnormalities persisted and were slower to resolve in the severe group⁷³. A further large retrospective Italian study of 405 patients with follow up between 5 to 7 months showed CT resolution in 55.6% of patients. Residual non fibrotic and fibrotic abnormalities were noted in 37.5% and 6.9% of patients respectively. Non fibrotic changes were described as overt GGO (4.9% of whole population) or barely visible GGO (27.2% of whole population), peripheral predominant bronchiectasis (12.8%), peri lobular opacities (7.9%) and peripheral parenchymal bands (2.7%), resembling an NSIP pattern with or without organising pneumonia features. Residual fibrotic abnormalities were found in 6.9% of patients of which a third were attributed to post ventilatory abnormalities. Fibrotic abnormalities included subpleural reticulation (3.7%), bronchiectasis (4%) and volume loss (2.2%)⁷⁴. A subset of 65 patients had further CT imaging at 12 months follow up. Nine (13.8%) had complete resolution at 12 months, 46 had non-fibrotic residual abnormalities at 5-7 months, of which 26 (40%) completely resolved and 20 (30.8%) had improvement but with residual changes. The remaining 10 (15.4%) with fibrotic abnormalities remained unchanged at 12 months⁷⁵. In multivariate analysis, length of hospital admission, smoking history and obesity have been identified as risk factors for persistent radiological abnormalities.⁷⁵

Table 4 Published reports on radiology findings post SARS-CoV-2 infection												
	MANDEL et al. ⁴⁴	YANG et al. ⁷⁰	ZHANG et al. ⁷³	FRIJA-MASSON et al. ⁶³	ROBEY et al. ⁵³	WILLI et al. ⁵⁰	ZHOU et al. ⁷¹	FAVERIO et al. ⁵⁴	SAFONT et al. ⁶⁷	FAVERIO et al. ⁵⁹	BESUTTI et al. ⁷⁴	TARRASO ⁶⁸
Type of study	Cross sectional study	Retrospective study	Retrospective longitudinal study	Retrospective study	Retrospective analysis	Systematic literature search of 31 studies	Prospective cohort study	Multicenter prospective observational cohort	multicenter prospective cohort	Multicenter prospective observational cohort	Retrospective study	Multicentre prospective observational cohort study
Country	United Kingdom (UK)	Greece	China	Paris, France	UK	Switzerland	Wuhan, China	Northern Italy	Spain	Northern Italy	Italy	Spain
Duration of follow up	Median 54 days (IQR 47-59)	Median 56 days after symptom onset	Various time points up to 12 weeks	3 months	8-18 weeks	9-90 days	4 months	6 months	2 months and 6 months after discharge	11-13 months	12 months	2 months and 12 months
Number of patients	384	116	310	137	221	48,258	216	312	313	287	65	325 ¹ 156 ²
Abnormal radiology	38% CXR remained abnormal 9% CXR deteriorating	46% with CT evidence of fibrotic changes	60.7% CT had abnormalities after 12 weeks	Overall % of abnormalities on CT not declared	65% of CT scans had abnormalities	54.3-83% had CT abnormalities	Abnormalities on CT scans 85.1% ¹ 68.0% ² 22.2% ³ (p-value <0.001)	Abnormalities on CT scans 25% ¹ 24% ² 44% ³ (p<0.001)	Abnormalities on CT scans 52.38% ¹ 91.14% ² (p-value 0.001)	Abnormalities on CT scans 46% ¹ 65% ² 80% ³ (p<0.001)	86.2% had ongoing CT abnormalities Residual non-fibrotic abnormalities(37.5%) ¹ Residual fibrotic abnormalities (4.4%) ² Post-ventilatory abnormalities(2.5%) ³	At 2 months 61.6% (200/325) had CT abnormalities and at 12 months 78.8% (123/156)
Specific Findings on CT scans												
Ground Glass Opacities (GGO)			51.6%	75%	44%		79.3% ¹ 60.0% ² 22.2% ³ (p-value<0.001)	16% ¹ 7% ² 12% ³ (p=00186)	36.73% ¹ 68.35% ² (p=0.001)	30% ¹ 48% ² 71% ³ (p<0.001)	32.1% at 5-7 months ¹ 3.5% at 5-7 months ² 2.2% at 5-7 months ³	73.5% ¹ (32% of cohort) 45.5% ² (15.8% of cohort)
Parenchymal bands		76%	32%		-				13.60% ¹ 38.46% ² (p=0.001)		2.7% at 5-7 months ¹	33.4% ² (11.6% of cohort)
Bronchiectasis		32%	11.5%		-		4.6% ¹ 0.0% ² 0.0% ³		8.16% ¹ 44.30% ² (p=0.001)	4% ¹ 2% ² 11% ³ (p=0.03)	12.8% at 5-7 months ¹ 4.0% at 5-7 months ² 2.2% at 5-7 months ³	30.8% ² (10.7% of entire cohort)
Lung distortion		25%			-							
Honeycombing		9%			-					0% ¹ 2% ² 1% ³	0.5% at 5-7 months ² 0.2% at 5-7 months ³	
Reticulation			5.7%	30%			11.5% ¹ 16.0% ² 0.0% ³ (p-value =0.019)	19% ¹ 19% ² 34% ³ (p<0.042)	10.88% ¹ 34.17% ² (p=0.001)	27% ¹ 42% ² 29% ³ (p<0.001)	3.7% at 5-7 months ² 1.7% at 5-7 months ³	33.9% ² (11.8% of entire cohort)
Fibrotic changes		89%	36.1%	18%	21%	1.8% - 47%		-			4.4%	65.4% ² (22.7% of entire cohort)
Comments		Patients more likely to have fibrotic changes were older and had a more severe form of COVID-19	Severe COVID-19 more likely to cause CT changes which persist longer	Patients with fibrosis on Ct also had impairments in PFT	Features of fibrosis on CT felt to be significant to patients who required ICU (p=0.0259)		severe/critical ¹ mild/moderate ² asymptomatic ³	¹ = Oxygen alone ² = CPAP ³ = IMV Abnormalities on CT were more frequent in patients requiring higher respiratory support	Moderate ¹ Severe ²	¹ = Oxygen alone ² = CPAP ³ = IMV	70.8% ¹ at 5-7months, of which 20 (30.8%) had residual changes. The remaining 10 (15.4%) with fibrotic c abnormalities remained unchanged at 12months	2 months ¹ 12 months ²

The Emergence of Post COVID Interstitial Lung Disease (PC-ILD)

Persistent symptoms, lung function and radiological abnormalities have been reported post COVID 19 (Table 1-3). Several studies have demonstrated gradual resolution of these findings over time including improvements in lung function impairment and radiological abnormalities^{20,48,54,56,58,59,68,76}. The COVID-FIBROTIC study of 448 patients demonstrated ongoing radiological abnormalities in 27.4% of the patients at 12 months, with GGO being the most common abnormality (15.8%) followed by reticular pattern (11.8%), traction bronchiectasis (10.7%) and parenchymal bands (11.6%). Overall residual fibrotic changes were noted at 12 months in 22.7% of the entire cohort. Residual fibrotic features have been noted at varying timepoints in studies extending out to a year⁶⁸. Risk factors for developing PC-ILD include increasing age (mean age 59 in fibrotic group vs 48.5 non-fibrotic group), Chronic Obstructive Pulmonary Disease (HR 2.88; 95% CI 1.27, 6.52) and severity of COVID-19 stratified according to baseline CT, requirement for non-invasive or IMV and prolonged length of stay^{51,53,54,56,58,59,63,65,71,72,74,76,77}.

A systematic review and meta-analysis of 46 studies assessing radiological features in 2811 CT images within 12 months found great heterogeneity in fibrotic findings between studies with a mean estimate of 29% (95% CI 22-37%)⁷⁷. Other meta-analysis have described the presence of fibrosis as high as 45%⁵⁶.

There remain several unanswered questions regarding PC-ILD. There is little doubt that a cohort of individuals have residual fibrotic changes at 12 months ranging from 1-29% in studies^{48,59,78} however pathologically whether that is related to fibrosis promoted by coronavirus itself or a sequelae of severe infection and IMV remains to be determined. Certainly, studies have shown the presence of fibrosis being highest amongst those mechanically ventilated^{54,58,59,65}. Similarly, it is unclear if COVID-19 unmask and accelerates an undiagnosed pre-existing ILD or if it acts as a provoking viral agent triggering ILD⁷⁹. Longer term studies are also needed to ascertain whether the fibrotic changes observed at a year, and consequently pulmonary function impairment and symptoms, continue to improve or remain static (similar to that seen in ARDS) over time. One such study, The UK Interstitial Lung Disease Long COVID study (UKILD-Long COVID) aims to investigate the prevalence and risk factors for PC-ILD looking at clinical, functional and imaging parameters over time⁷.

Treatment of PC-ILD:

A greater understanding of the pathophysiological mechanisms by which COVID-19 contributes to the development of lung fibrosis is key to our understanding of the natural history and development of PC-ILD. This in turn may lead us to the development of therapies that could ameliorate or hasten resolution.

The beneficial role of Dexamethasone in acutely unwell COVID-19 patients has been demonstrated in a randomised controlled trial⁸⁰. There is limited trial evidence of therapy for PC-ILD. The majority of data are from observational cohorts. In a study of 837 patients followed up 4 weeks after discharge, 325 had ongoing symptoms and were offered further investigations and assessment. 35 (4.8%) patients were given the diagnosis of PC-ILD – predominantly an organising pneumonia pattern. 30 patients were treated with corticosteroid therapy at day 61 (+/- 19) post COVID which was weaned over a period of 3 weeks. Patients reported symptomatic (median MRC improved from 3 (± 2) to 2 (± 1); $p=0.002$), physiological (mean relative increase in FVC of 9.6% (± 13.6); $p=0.004$ and mean increase in T_{LCO} of 31.49% (± 27.7); $p<0.001$) and radiological improvements. There was no observation of progression of CT findings or change to fibrosis after treatment with corticosteroids. This study was limited due to the lack of randomisation and control arm⁸¹.

Furthermore, the potential role of antifibrotics has been studied in a small retrospective, matched case-control study of 21 patients who received nintedanib therapy. There were improvements in SpO_2/FiO_2 ratio ($p=0.006$) with no differences in chest imaging or oxygenation between the nintedanib and the control group⁸². To date, only a few observational studies have investigated the role of immunomodulatory and antifibrotic therapies highlighting the great need for randomised control trials⁸³.

Novel therapies targeting histone deacetylase (HDAC)⁸⁸ and Hepatocyte Growth Factor (HGF) secreted by Mesenchymal Stem Cells have been proposed due to their antifibrotic effects^{84,85}. A phase 1 clinical trial in 27 patients with COVID-19 pulmonary fibrosis using human embryonic stem cell–derived immunity- and matrix-regulatory cells (hESC-IMRCs) during the SARS-CoV-2 outbreak in Wuhan City showed improvements in exercise capacity and resolution of fibrotic changes on CT⁸⁶. There are ongoing trials of Sirolimus, Pirfenidone and Colchicine assessing the impact on the development of PC-ILD^{83,87,88} and we eagerly await robust trials investigating therapies in PC-ILD.

Summary:

The long-term impact of the COVID-19 pandemic remains to be elucidated. The SARS-CoV-2 virus triggers a significant inflammatory and immune response, which causes lung damage. Though the majority of patients will improve and recover fully, some have persistent symptoms, reduced lung function and radiological abnormalities at 12 months. With over 550 million people affected world-wide the significance of persistent pulmonary abnormalities in the form of pulmonary fibrosis cannot be under-estimated in terms of ongoing morbidity. The incidence of PC-ILD is very heterogenous and varies from study to study, according to varied factors including the duration of follow up, severity of SARS-CoV-2 infection and need for IMV, as well as other potential risk factors. Further studies are eagerly awaited that will glean more light on the risk factors for developing PC-ILD, the role of therapies in preventing or treating PC-ILD and give a greater understanding of the clinical significance of this new disease.

Clinic Care Points:

- Persistent pulmonary symptoms are commonly reported post SARS-CoV-2 infection and risk factors include increased length of stay in hospital with COVID-19, severe COVID-19 pneumonitis on initial CT, the need for higher respiratory support, female gender and increasing age .
- Lung function impairment improves over time, however can persist in a proportion of patients post SARS-CoV-2 infection
- CT abnormalities at one year include mostly non-fibrotic changes (like ground glass opacities, bronchiectasis, peri lobular opacities and parenchymal bands) and less commonly peripheral fibrotic changes.
- The long term consequences of persistent fibrotic changes post COVID-19 remain to be elucidated and studies need to assess the significance of these findings.

References

1. Ghebreyesus TA . WHO Director-General's opening remarks at the media briefing on COVID-19. In: World Health Organization. 2020. Available at [WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020](#). Accessed September 9, 2022
2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine* 2020;382(8):727-733.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. In: World Health Organization 2022. Available at [WHO Coronavirus \(COVID-19\) Dashboard | WHO Coronavirus \(COVID-19\) Dashboard With Vaccination Data](#). Accessed September 9, 2022.
4. Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy* 2021;76(2):428-455.
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020;395(10229):1054-1062.
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA* 2020;323(13):1239.
7. Wild JM, Porter JC, Molyneaux PL, et al. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). *BMJ Open Respiratory Research* 2021;8(1):e001049.
8. Drożdżal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. *Drug Resistance Updates* 2021;59:100794.
9. Parums D v. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. *Medical Science Monitor* 2022;28: e935952
10. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine* 2022;386(15):1397-1408.

11. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021;Preprint(21258639).
12. Imran Mohd, Kumar Arora M, Asdaq SMB, et al. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. *Molecules* 2021;26(19):5795.
13. Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. *BMJ* 2021;375:n2422.
14. Office for National Statistics. Coronavirus (COVID-19) latest insights. In:Office for National Statistics 2022. Available at [Coronavirus \(COVID-19\) latest insights - Office for National Statistics \(ons.gov.uk\)](https://ons.gov.uk/coronavirus). Accessed September 10, 2022.
15. Centers for Disease Control and Prevention . CDC COVID Data Tracker: Daily and Total Trends. In: Centers for Disease Control and Prevention 2022. Available at [CDC COVID Data Tracker: Daily and Total Trends](https://covid.cdc.gov/covid-data-tracker/#total-trends). Accessed August 25, 2022.
16. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *The Lancet Respiratory Medicine* 2020;8(8):807-815.
17. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax* 2020;75(11):1009-1016.
18. Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian Journal of Radiology and Imaging* 2017;27(03):342-349.
19. Xie L, Liu Y, Fan B, et al. Dynamic changes of serum SARS-Coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. *Respiratory Research* 2005;6(1):5.
20. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. *The Lancet Respiratory Medicine* 2021;9(7):747-754.
21. Zhao L, Wang X, Xiong Y, Fan Y, Zhou Y, Zhu W. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. *Medicine* 2021;100(12):e25232.

22. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *The Lancet Infectious Diseases* 2020;20(10):1135-1140.
23. Ducloyer M, Gaborit B, Toquet C, et al. Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. *Int J Legal Med.* 2020;134(6):2209-2214.
24. Grillo F, Barisione E, Ball L, Mastracci L, Fiocca R. Lung fibrosis: an undervalued finding in COVID-19 pathological series. *The Lancet Infectious Diseases.* 2021;21(4):e72.
25. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. *J Med Virol.*2020;92(6):612-617.
26. Sinha P, Bos LD. Pathophysiology of the Acute Respiratory Distress Syndrome. *Critical Care Clinics* 2021;37(4):795-815.
27. Lai CC, Shih TP, Ko WC, et al.. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents* 2020;55(3):105924.
28. Mcdonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? *Am J Physiol Lung Cell Mol Physiol* 2021;320(2):L257-L265.
29. Ware LB, Matthay MA. The Acute Respiratory Distress Syndrome. *New England Journal of Medicine* 2000 ;342(18):1334-1349.
30. Thille AW, Esteban A, Fernández-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. *The Lancet Respiratory Medicine* 2013;1(5):395-401.
31. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020;368(6490):473-474.
32. Ye C, Li H, Bao M, et al. Alveolar macrophage - derived exosomes modulate severity and outcome of acute lung injury. *Aging* 2020;12(7):6120-6128.

33. Deng Y, Herbert JA, Robinson E, et al. Neutrophil-Airway Epithelial Interactions Result in Increased Epithelial Damage and Viral Clearance during Respiratory Syncytial Virus Infection. *Journal of Virology* 2020;94(13):e02161-19.
34. Herbert JA, Deng Y, Hardelid P, et al. β_2 -integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection. *European Respiratory Journal* 2020;56(2):1902216.
35. John AE, Joseph C, Jenkins G, et al. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. *Immunological Reviews* 2021;302(1):228-240.
36. Melms JC, Biermann J, Huang H, et al. A molecular single-cell lung atlas of lethal COVID-19. *Nature* 2021;595(7865):114-119.
37. Wang S, Yao X, Ma S, et al. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. *Nature Cell Biology* 2021;23(12):1314-1328.
38. Zhang C, Zhao Wu |, Li JW, et al. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. *J Med Virol* 2021;93:1378-1386.
39. Weber A, Trapasso F, Graecia" Of Catanzaro M, et al. Signaling in fibrosis: TGF- β , wNT, and YAP/TAZ converge. *Front Med (Lausanne)*2015;2(59).
40. Cabrera-Benítez NE, Parotto M, Post M, et al. Mechanical stress induces lung fibrosis by epithelial–mesenchymal transition*. *Critical Care Medicine*. 2012;40(2):510-517.
41. Zhang R, Pan Y, Fanelli V, et al. Mechanical Stress and the Induction of Lung Fibrosis via the Midkine Signaling Pathway. *Am J Respir Crit Care Med* 2015;192(3):315-323.
42. Wei J, Yang H, Lei P, et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. *Journal of X-Ray Science and Technology* 2020;28(3):383-389.
43. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188). In: London: National Institute for Health and Care Excellence (NICE). 2021. Available at

Accessed September 10, 2022.

44. Mandal S, Barnett J, Brill SE, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax* 2021;76(4):396-398.
45. Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *The Lancet Respiratory Medicine* 2021;9(11):1275-1287.
46. Evans RA, Leavy OC, Richardson M, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. *The Lancet Respiratory Medicine* 2022;10(8):761-775.
47. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;324(6):603.
48. Vargas Centanaro G, Calle Rubio M, Álvarez-Sala Walther JL, et al. Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study. *Open Forum Infectious Diseases* 2022;9(4).
49. Chun HJ, Coutavas E, Pine AB, et al. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. *JCI Insight* 2021;6(14).
50. Willi S, Lüthold R, Hunt A, et al. COVID-19 sequelae in adults aged less than 50 years: A systematic review. *Travel Medicine and Infectious Disease* 2021;40:101995.
51. Froidure A, Mahsouli A, Liistro G, et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. *Respiratory Medicine*. 2021;181:106383.
52. Boari GEM, Bonetti S, Braglia-Orlandini F, et al. Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study. *High Blood Pressure & Cardiovascular Prevention* 2021;28(4):373-381.
53. Robey RC, Kemp K, Hayton P, et al. Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. *Advances in Therapy* 2021;38(8):4505-4519.
54. Faverio P, Luppi F, Rebora P, et al. Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study. *Respiration* 2021;100(11):1078-1087.

55. Han X, Fan Y, Alwalid O, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. *Radiology* 2021;299(1):E177-E186.
56. Hama Amin BJ, Kakamad FH, Ahmed GS, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. *Annals of Medicine and Surgery* 2022;77:103590.
57. Zangrillo A, Belletti A, Palumbo D, et al. One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation. *Journal of Cardiothoracic and Vascular Anesthesia* 2022;36(5):1354-1363.
58. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *The Lancet*. 2021;398(10302):747-758.
59. Faverio P, Luppi F, Rebora P, et al. One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study. *Respiratory Research* 2022;23(1):65.
60. Eksombatchai D, Wongsinin T, Phongnarudech T, et al.. Pulmonary function and six-minute-walk test in patients after recovery from COVID-19: A prospective cohort study. *PLOS ONE*. 2021;16(9):e0257040.
61. Lv D, Chen X, Wang X, et al. Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study. *Annals of Palliative Medicine* 2020;9(5):3447-3452.
62. Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. *Thorax* 2021;76(4):402-404.
63. Frija-Masson J, Debray MP, Boussouar S, et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. *Respiratory Medicine* 2021;184:106435.
64. Guler SA, Ebner L, Aubry-Beigelman C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. *European Respiratory Journal* 2021;57(4):2003690.
65. Noel-Savina E, Viatgé T, Faviez G, et al. Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months. *Respiratory Medicine and Research*. 2021;80:100822.

66. Hellemons ME, Huijts S, Bek LM, et al. Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes. *Annals of the American Thoracic Society* 2022;19(4):551-561.
67. Safont B, Tarraso J, Rodriguez-Borja E, et al. Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months After Hospital Discharge. *Archivos de Bronconeumología* 2022;58(2):142-149.
68. Tarraso J, Safont B, Carbonell-Asins JA, et al. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. *Respiratory Research* 2022;23(1):242.
69. Marvisi M, Ferrozzi F, Balzarini L, et al.. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. *International Journal of Infectious Diseases* 2020;99:485-488.
70. Yang ZL, Chen C, Huang L, et al. Fibrotic Changes Depicted by Thin-Section CT in Patients With COVID-19 at the Early Recovery Stage: Preliminary Experience. *Frontiers in Medicine* 2020;7:605088.
71. Zhou M, Xu J, Liao T, et al. Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. *Frontiers in Medicine* 2021;8:682087.
72. Cocconcelli E, Bernardinello N, Giraudo C, et al. Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia. *Frontiers in Medicine* 2022;8:823600
73. Zhang D, Zhang C, Li X, et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. *European Radiology* 2021;31(9):7172-7183.
74. Besutti G, Monelli F, Schirò S, et al. Follow-Up CT Patterns of Residual Lung Abnormalities in Severe COVID-19 Pneumonia Survivors: A Multicenter Retrospective Study. *Tomography* 2022;8(3):1184-1195.
75. Wallis TJM, Heiden E, Horno J, et al. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. *Respiratory Research* 2021;22(1):157.

76. Caruso D, Guido G, Zerunian M, et al. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. *Radiology* 2021;301(2):E396-E405.
77. Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. *Thorax* 2022; Published online :thoraxjnl-2021-218275.
78. Bocchino M, Lieto R, Romano F, et al. Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia. *Radiology* 2022;305(2):479-485
79. Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. *Intensive Care Medicine* 2022;1-4:Published online September 8, 2022.
80. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. *The New England journal of medicine* 2021;384(8):693-704.
81. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. *Annals of the American Thoracic Society* 2021;18(5):799-806.
82. Saiphoklang N, Patanayindee P, Ruchiwit P. The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. *Critical Care Research and Practice* 2022;2022:1-7.
83. Molina M. Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19. In: *ClinicalTrials.gov*. 2021. Available at [Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19 - Full Text View - ClinicalTrials.gov](#). Accessed October 10, 2022.
84. P KM, Sivashanmugam K, Kandasamy M, et al. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF- β signalling in COVID-19 survivors. *Life Sciences* 2021;266:118883.
85. Vishnupriya M, Naveenkumar M, Manjima K, et al. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells - How the lung heals. *European review for medical and pharmacological sciences*. 2021;25(6):2748-2751.

86. Wu J, Zhou X, Tan Y, et al. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs. *Cell Proliferation* 2020;53(12):e12944.
87. University of Chicago. Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis. In: ClinicalTrials.gov. 2021, Available at [Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis - Full Text View - ClinicalTrials.gov](#). Accessed October 10, 2022..
88. Issak ER. Colchicine and Post-COVID-19 Pulmonary Fibrosis. In: ClinicalTrials.gov, 2021. Available at [Colchicine and Post-COVID-19 Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov](#). Accessed October 10, 2022.